Medicare Enrolled
Dr. Paul Snyder, MD
Dermatology · Dartmouth, MA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Snyder from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Snyder?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Snyder
Dr. Paul Snyder is a dermatology specialist in Dartmouth, MA, with 21 years of NPI registration. Based on federal Medicare data, Dr. Snyder performed 4,211 Medicare services across 1,822 unique beneficiaries.
Between the years covered by Open Payments, Dr. Snyder received a total of $3,961 from 28 pharmaceutical and/or device companies across 172 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in dermatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Snyder is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 21 years in practice
▲ Top 21% volume in MA
$3,961 industry payments
Medicare Practice Summary
Medicare Utilization ↗4,211
Medicare services
Top 21% in MA for dermatology
1,822
Unique beneficiaries
$66
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~201 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Destruction of precancerous skin growths, 2-14 This procedure involves the removal or destruction of two to fourteen precancerous skin lesions. It is performed to eliminate abnormal skin cells that have the potential to develop into cancer. |
1,261 | $5 | $50 |
| UV therapy with tar or petroleum jelly A treatment using ultraviolet radiation combined with the application of tar or petroleum jelly to the skin. |
1,055 | $99 | $275 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
391 | $70 | $250 |
| Destruction of precancerous skin growth, 1 Removal of a single precancerous skin growth. This procedure destroys abnormal skin cells to prevent them from developing into cancer. |
351 | $41 | $175 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
241 | $99 | $325 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
216 | $19 | $100 |
| Destruction of skin growths (warts/lesions), 1-14 This procedure involves the removal or destruction of one to fourteen skin growths. It is a minor surgical intervention performed on the skin surface. |
130 | $88 | $275 |
| Skin biopsy, tangential A procedure to remove a sample of the first identified skin growth for laboratory examination. |
96 | $69 | $250 |
| Destruction of cancer skin growth, 1.1-2.0 cm Removal of a cancerous skin growth on the trunk, arms, or legs that measures between 1.1 and 2.0 centimeters. |
57 | $110 | $450 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
49 | $44 | $200 |
| Destruction of 15 or more precancerous skin growths This procedure involves the removal or destruction of fifteen or more precancerous skin lesions. It is performed to treat abnormal skin cells that have the potential to develop into cancer. |
42 | $138 | $400 |
| Destruction of cancer skin growth, 0.6-1.0 cm This procedure involves the removal or destruction of a cancerous skin growth located on the trunk, arms, or legs that measures between 0.6 and 1.0 centimeters. |
35 | $95 | $375 |
| Topical aminolevulinic acid HCl 20% solution A topical medication applied to the skin for medical treatment. It is supplied as a single-unit dosage form containing 354 mg of the active ingredient. |
35 | $300 | $450 |
| Surgical removal of facial skin cancer, 1.1-2.0 cm This procedure involves the surgical excision of a cancerous skin growth located on the face, ears, eyelids, nose, lips, or mouth. The size of the removed tissue is between 1.1 and 2.0 centimeters. |
33 | $113 | $600 |
| Intermediate wound repair, 2.6-7.5 cm A medical procedure to close a wound on the scalp, underarms, trunk, arms, or legs that measures between 2.6 and 7.5 centimeters. This type of repair involves cleaning the wound and stitching it closed to promote healing. |
27 | $246 | $700 |
| Complicated wound repair, 2.6-7.5 cm A complex surgical procedure to close a wound measuring between 2.6 and 7.5 centimeters on areas such as the face, neck, hands, or feet. |
27 | $395 | $1,100 |
| Light therapy to destroy precancerous skin growth A qualified healthcare professional applies light to the skin to destroy precancerous growths. |
21 | $190 | $500 |
| Complicated wound repair, scalp/arms/legs, 2.6-7.5 cm A complex surgical procedure to close a wound on the scalp, arms, or legs that measures between 2.6 and 7.5 centimeters in length. |
16 | $350 | $1,000 |
| Skin cancer removal, face/ears/eyes/nose/lips, 2.1-3.0 cm Surgical removal of a cancerous skin growth from the face, ears, eyelids, nose, lips, or mouth. The procedure involves excising a lesion measuring between 2.1 and 3.0 centimeters. |
15 | $133 | $650 |
| Destruction of cancerous skin growth on face, 0.6-1.0 cm This procedure involves the removal or destruction of a cancerous skin lesion located on the face, ears, eyelids, nose, lips, or mouth. The lesion treated measures between 0.6 and 1.0 centimeters in diameter. |
15 | $131 | $400 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | 13 | $250 | $750 |
| Destruction of skin growth, 15 or more growths | 13 | $99 | $325 |
| Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 13 | $135 | $500 |
| Light therapy to destroy precancerous skin growth This procedure uses light to treat and remove precancerous skin lesions. It is a method for destroying abnormal skin cells before they become cancerous. |
13 | $121 | $400 |
| Additional skin growth biopsy Removal of a sample of an additional skin growth for laboratory examination. This code is used for each extra lesion biopsied during the same session. |
12 | $43 | $150 |
| Complex repair of eyelid, nose, ear, or lip wound, 2.6-7.5 cm A surgical procedure to repair a complex wound on the eyelid, nose, ear, or lip that measures between 2.6 and 7.5 centimeters. |
12 | $411 | $1,200 |
| Surgical removal of skin cancer, 1.1-2.0 cm Surgical excision of a cancerous skin growth measuring between 1.1 and 2.0 centimeters on the body, arms, or legs. |
11 | $104 | $550 |
| Surgical removal of skin cancer, 2.1-3.0 cm This procedure involves the surgical excision of a cancerous skin growth located on the body, arms, or legs. The size of the removed tissue measures between 2.1 and 3.0 centimeters. |
11 | $118 | $600 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$3,961
Total received (2018-2024)
Avg $660/year across 6 years
Top 30% in MA for dermatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
28
Companies
172
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,362 (84.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$598 (15.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,087
2023
$672
2022
$529
2021
$334
2019
$520
2018
$818
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$253
LEO Pharma Inc.
$151
Janssen Biotech, Inc.
$126
Regeneron Healthcare Solutions, Inc.
$87
Lilly USA, LLC
$83
Amgen Inc.
$67
REVANCE THERAPEUTICS, INC.
$64
E.R. Squibb & Sons, L.L.C.
$64
Novartis Pharmaceuticals Corporation
$46
Fresenius Kabi USA, LLC
$28
PFIZER INC.
$27
Ortho Dermatologics, a division of Bausch Health US, LLC
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$20
Merck Sharp & Dohme LLC
$20
UCB, Inc.
$18
GENZYME CORPORATION
$15
Top 3 companies account for 48.7% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$636
LEO Pharma Inc.
$500
Novartis Pharmaceuticals Corporation
$371
ABBVIE INC.
$352
Regeneron Healthcare Solutions, Inc.
$231
AbbVie Inc.
$214
PFIZER INC.
$210
Amgen Inc.
$178
Lilly USA, LLC
$175
GENZYME CORPORATION
$152
Incyte Corporation
$146
Merz North America, Inc.
$97
E.R. Squibb & Sons, L.L.C.
$95
UCB, Inc.
$92
AbbVie, Inc.
$87
REVANCE THERAPEUTICS, INC.
$64
DUSA Pharmaceuticals, Inc.
$61
Sun Pharmaceutical Industries Inc.
$54
Galderma Laboratories, L.P.
$49
Allergan, Inc.
$32
Fresenius Kabi USA, LLC
$28
Janssen Scientific Affairs, LLC
$27
Ortho Dermatologics, a division of Bausch Health US, LLC
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$20
Merck Sharp & Dohme LLC
$20
Celgene Corporation
$18
Bayer HealthCare Pharmaceuticals Inc.
$17
Allergan Inc.
$15
Top 3 companies account for 38.0% of all-time payments
Associated products mentioned in payments ›
20% · ABSORICA (isotretinoin) · ADBRY · BLU-U Blue Light Photodynamic Therapy Illuminator Model 4170 · BOTOX · BOTOX COSMETIC · Bimzelx · CIBINQO · COSENTYX · Cimzia · DAXXIFY · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · ENSTILAR · EPIDUO FORTE · EUCRISA · Enbrel · Finacea · HUMIRA · Humira · IDACIO · ILUMYA · JUBLIA · KEYTRUDA · LIBTAYO · Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution · OPZELURA · ORACEA · Otezla · REMICADE · RINVOQ · SKYRIZI · SPEVIGO · STELARA · Skyrizi · Sotyktu · TALTZ · TREMFYA · Tremfya · Winlevi
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (85%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Dermatologists within 10 mi
70
Per 100K population
12.1
County median income
$84,198
Nearest hospital
SOUTHCOAST BEHAVIORAL HEALTH
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Snyder is a clinical cardiology specialist, with above-average Medicare volume (top 21% in MA), with low-engagement industry engagement, with 21 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Snyder experienced with destruction of precancerous skin growths, 2-14?
Based on Medicare claims data, Dr. Snyder performed 1,261 destruction of precancerous skin growths, 2-14 services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Snyder receive payments from pharmaceutical companies?
Yes. Dr. Snyder received a total of $3,961 from 28 companies across 172 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Snyder's costs compare to other dermatologists in Dartmouth?
Dr. Snyder's average Medicare payment per service is $66. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Snyder) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Dermatologists in Dartmouth
Browse dermatologists in Dartmouth ranked by procedure volume and transparency data.
Highest volume
Top Dermatologists in MA
Dermatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Dermatologists in MA
Which MA dermatologists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
LEO Pharma Inc. Payments to Doctors
See all physicians who received payments from LEO Pharma Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology